drugset / Trial / NCT00642707

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

NCT00642707 ↗

Phase 2 Completed 44 enrolled CytoDyn, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is: 1. To assess the antiviral activity of PRO 140 2. To assess the safety and tolerability of PRO 140 3. To generate additional PK, PD and safety data of PRO 140

Timeline

Start
2008-03
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Leronlimab Monoclonal antibody 162 mg Subcutaneous
Comparator Leronlimab Monoclonal antibody 324 mg Subcutaneous